Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 44 | 43 | −1 |
| Shares | 12.9M | 13.1M | +203.5K (+1.6%) |
| Value | $277.4M | $294.2M | +$16.9M (+6.1%) |
New holders (2)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Allspring Global Investments Holdings, LLC | 12,885 | $289.0K | 0.00% |
| Dimensional Fund Advisors LP | 8,990 | $202.0K | 0.00% |
Sold out (3)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| J. Goldman & Co LP | 22,198 | $478.0K |
| Virtus ETF Advisers LLC | 6,008 | $129.0K |
| Parallel Advisors, LLC | 44 | $1.00K |